Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

PLRZ vs SIGA vs AGEN vs NVAX vs NRXP

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PLRZ
Polyrizon Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$59M
5Y Perf.-95.3%
SIGA
SIGA Technologies, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$339M
5Y Perf.-33.5%
AGEN
Agenus Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$132M
5Y Perf.-9.0%
NVAX
Novavax, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.50B
5Y Perf.+5.2%
NRXP
NRx Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$85M
5Y Perf.+124.8%

PLRZ vs SIGA vs AGEN vs NVAX vs NRXP — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PLRZ logoPLRZ
SIGA logoSIGA
AGEN logoAGEN
NVAX logoNVAX
NRXP logoNRXP
IndustryBiotechnologyDrug Manufacturers - Specialty & GenericBiotechnologyBiotechnologyBiotechnology
Market Cap$59M$339M$132M$1.50B$85M
Revenue (TTM)$0.00$94M$114M$596M$242K
Net Income (TTM)$-958K$-4.04T$115K$-88M$-38M
Gross Margin61.8%35.7%84.6%59.5%
Operating Margin27.7%-17.7%-11.2%-63.0%
Forward P/E28.3x2.8x2.9x3.6x
Total Debt$0.00$595K$10M$249M$631K
Cash & Equiv.$3M$155M$3M$241M$8M

PLRZ vs SIGA vs AGEN vs NVAX vs NRXPLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PLRZ
SIGA
AGEN
NVAX
NRXP
StockOct 24May 26Return
Polyrizon Ltd. (PLRZ)1004.7-95.3%
SIGA Technologies, … (SIGA)10066.5-33.5%
Agenus Inc. (AGEN)10091.0-9.0%
Novavax, Inc. (NVAX)100105.2+5.2%
NRx Pharmaceuticals… (NRXP)100224.8+124.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: PLRZ vs SIGA vs AGEN vs NVAX vs NRXP

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SIGA and AGEN are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Agenus Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. NRXP and PLRZ also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
PLRZ
Polyrizon Ltd.
The Defensive Pick

PLRZ is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.66, current ratio 10.16x
  • Beta 0.66, current ratio 10.16x
  • Beta 0.66 vs AGEN's 2.72
Best for: sleep-well-at-night and defensive
SIGA
SIGA Technologies, Inc.
The Income Pick

SIGA has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.

  • Dividend streak 4 yrs, beta 1.15, yield 12.7%
  • 7.6% 10Y total return vs NVAX's -90.4%
  • Better valuation composite
  • 12.7% yield; 4-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability and long-term compounding
AGEN
Agenus Inc.
The Quality Compounder

AGEN is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 0.1% margin vs SIGA's -43K%
  • 0.1% ROA vs NRXP's -489.9%
Best for: quality and efficiency
NVAX
Novavax, Inc.
The Growth Play

NVAX is the clearest fit if your priority is growth exposure.

  • Rev growth 64.7%, EPS growth 306.5%, 3Y rev CAGR -11.1%
Best for: growth exposure
NRXP
NRx Pharmaceuticals, Inc.
The Growth Leader

NRXP ranks third and is worth considering specifically for growth and momentum.

  • 101.1% revenue growth vs PLRZ's -7.5%
  • +55.3% vs PLRZ's -91.3%
Best for: growth and momentum
See the full category breakdown
CategoryWinnerWhy
GrowthNRXP logoNRXP101.1% revenue growth vs PLRZ's -7.5%
ValueSIGA logoSIGABetter valuation composite
Quality / MarginsAGEN logoAGEN0.1% margin vs SIGA's -43K%
Stability / SafetyPLRZ logoPLRZBeta 0.66 vs AGEN's 2.72
DividendsSIGA logoSIGA12.7% yield; 4-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)NRXP logoNRXP+55.3% vs PLRZ's -91.3%
Efficiency (ROA)AGEN logoAGEN0.1% ROA vs NRXP's -489.9%

PLRZ vs SIGA vs AGEN vs NVAX vs NRXP — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PLRZPolyrizon Ltd.

Segment breakdown not available.

SIGASIGA Technologies, Inc.
FY 2025
Product Sales and Supportive Services
93.1%$88M
Research and Development
6.9%$7M
AGENAgenus Inc.
FY 2025
Non Cash Royalty Revenue
99.1%$109M
Other
0.9%$1M
NVAXNovavax, Inc.
FY 2025
Product
50.0%$685M
Nuvaxovid Sales
45.6%$625M
Supply Sales
4.4%$60M
NRXPNRx Pharmaceuticals, Inc.
FY 2025
Therapy
100.0%$854,000

PLRZ vs SIGA vs AGEN vs NVAX vs NRXP — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLAGENLAGGINGNRXP

Income & Cash Flow (Last 12 Months)

AGEN leads this category, winning 3 of 6 comparable metrics.

NVAX and PLRZ operate at a comparable scale, with $596M and $0 in trailing revenue. AGEN is the more profitable business, keeping 0.1% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, AGEN holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPLRZ logoPLRZPolyrizon Ltd.SIGA logoSIGASIGA Technologies…AGEN logoAGENAgenus Inc.NVAX logoNVAXNovavax, Inc.NRXP logoNRXPNRx Pharmaceutica…
RevenueTrailing 12 months$0$94M$114M$596M$242,000
EBITDAEarnings before interest/tax$120,688$26M-$10M-$47M-$31M
Net IncomeAfter-tax profit-$957,656-$4.04T$115,000-$88M-$38M
Free Cash FlowCash after capex-$812,228$33M-$159M-$96M-$12M
Gross MarginGross profit ÷ Revenue+61.8%+35.7%+84.6%+59.5%
Operating MarginEBIT ÷ Revenue+27.7%-17.7%-11.2%-63.0%
Net MarginNet income ÷ Revenue-43117.4%+0.1%-14.7%-157.3%
FCF MarginFCF ÷ Revenue+35.2%-139.1%-16.1%-49.0%
Rev. Growth (YoY)Latest quarter vs prior year-11.3%+27.5%-79.1%
EPS Growth (YoY)Latest quarter vs prior year+56.2%+85.3%-102.0%-80.0%
AGEN leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — SIGA and AGEN each lead in 2 of 5 comparable metrics.

At 3.6x trailing earnings, NVAX trades at a 87% valuation discount to PLRZ's 28.3x P/E. On an enterprise value basis, NVAX's 2.6x EV/EBITDA is more attractive than SIGA's 7.6x.

MetricPLRZ logoPLRZPolyrizon Ltd.SIGA logoSIGASIGA Technologies…AGEN logoAGENAgenus Inc.NVAX logoNVAXNovavax, Inc.NRXP logoNRXPNRx Pharmaceutica…
Market CapShares × price$59M$339M$132M$1.5B$85M
Enterprise ValueMkt cap + debt − cash$57M$185M$140M$1.5B$78M
Trailing P/EPrice ÷ TTM EPS28.28x14.33x-1102.94x3.63x-2.28x
Forward P/EPrice ÷ next-FY EPS est.2.78x2.94x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple7.60x2.56x
Price / SalesMarket cap ÷ Revenue3.58x1.16x1.34x69.15x
Price / BookPrice ÷ Book value/share8.00x1.70x
Price / FCFMarket cap ÷ FCF6.96x
Evenly matched — SIGA and AGEN each lead in 2 of 5 comparable metrics.

Profitability & Efficiency

AGEN leads this category, winning 3 of 8 comparable metrics.

PLRZ delivers a -5.2% return on equity — every $100 of shareholder capital generates $-5 in annual profit, vs $-11 for SIGA. On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs PLRZ's 3/9, reflecting solid financial health.

MetricPLRZ logoPLRZPolyrizon Ltd.SIGA logoSIGASIGA Technologies…AGEN logoAGENAgenus Inc.NVAX logoNVAXNovavax, Inc.NRXP logoNRXPNRx Pharmaceutica…
ROE (TTM)Return on equity-5.2%-10.7%
ROA (TTM)Return on assets-5.1%-7.4%+0.1%-7.4%-4.9%
ROICReturn on invested capital-65.4%+33.7%
ROCEReturn on capital employed-48.7%+11.3%+100.4%
Piotroski ScoreFundamental quality 0–935655
Debt / EquityFinancial leverage0.00x
Net DebtTotal debt minus cash-$3M-$154M$7M$8M-$7M
Cash & Equiv.Liquid assets$3M$155M$3M$241M$8M
Total DebtShort + long-term debt$0$595,169$10M$249M$631,000
Interest CoverageEBIT ÷ Interest expense-0.30x1.11x-5.10x-24.18x
AGEN leads this category, winning 3 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

NVAX leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in SIGA five years ago would be worth $10,136 today (with dividends reinvested), compared to $92 for NRXP. Over the past 12 months, NRXP leads with a +55.3% total return vs PLRZ's -91.3%. The 3-year compound annual growth rate (CAGR) favors NVAX at 7.4% vs PLRZ's -66.8% — a key indicator of consistent wealth creation.

MetricPLRZ logoPLRZPolyrizon Ltd.SIGA logoSIGASIGA Technologies…AGEN logoAGENAgenus Inc.NVAX logoNVAXNovavax, Inc.NRXP logoNRXPNRx Pharmaceutica…
YTD ReturnYear-to-date+10.9%-15.0%+16.1%+29.5%+16.8%
1-Year ReturnPast 12 months-91.3%+1.5%+27.1%+55.1%+55.3%
3-Year ReturnCumulative with dividends-96.4%+22.2%-88.2%+23.9%-50.6%
5-Year ReturnCumulative with dividends-96.4%+1.4%-93.9%-94.8%-99.1%
10-Year ReturnCumulative with dividends-96.4%+764.0%-94.3%-90.4%-96.8%
CAGR (3Y)Annualised 3-year return-66.8%+6.9%-51.0%+7.4%-21.0%
NVAX leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PLRZ and NRXP each lead in 1 of 2 comparable metrics.

PLRZ is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.7% from its 52-week high vs PLRZ's 6.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPLRZ logoPLRZPolyrizon Ltd.SIGA logoSIGASIGA Technologies…AGEN logoAGENAgenus Inc.NVAX logoNVAXNovavax, Inc.NRXP logoNRXPNRx Pharmaceutica…
Beta (5Y)Sensitivity to S&P 5000.65x1.09x2.58x2.22x1.89x
52-Week HighHighest price in past year$211.25$9.62$7.34$11.97$3.84
52-Week LowLowest price in past year$0.55$4.29$2.71$5.80$1.62
% of 52W HighCurrent price vs 52-week peak+6.7%+49.2%+51.1%+77.1%+79.7%
RSI (14)Momentum oscillator 0–10052.547.048.864.464.7
Avg Volume (50D)Average daily shares traded42K688K814K4.4M913K
Evenly matched — PLRZ and NRXP each lead in 1 of 2 comparable metrics.

Analyst Outlook

SIGA leads this category, winning 1 of 1 comparable metric.

Analyst consensus: SIGA as "Buy", AGEN as "Buy", NVAX as "Buy". Consensus price targets imply 95.5% upside for AGEN (target: $7) vs 95.0% for NVAX (target: $18). SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.

MetricPLRZ logoPLRZPolyrizon Ltd.SIGA logoSIGASIGA Technologies…AGEN logoAGENAgenus Inc.NVAX logoNVAXNovavax, Inc.NRXP logoNRXPNRx Pharmaceutica…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$7.33$18.00
# AnalystsCovering analysts11123
Dividend YieldAnnual dividend ÷ price+12.7%
Dividend StreakConsecutive years of raises411
Dividend / ShareAnnual DPS$0.60
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.1%+0.3%0.0%
SIGA leads this category, winning 1 of 1 comparable metric.
Key Takeaway

AGEN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NVAX leads in 1 (Total Returns). 2 tied.

Best OverallAgenus Inc. (AGEN)Leads 2 of 6 categories
Loading custom metrics...

PLRZ vs SIGA vs AGEN vs NVAX vs NRXP: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PLRZ or SIGA or AGEN or NVAX or NRXP a better buy right now?

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PLRZ or SIGA or AGEN or NVAX or NRXP?

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Polyrizon Ltd. at 28. 3x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — PLRZ or SIGA or AGEN or NVAX or NRXP?

Over the past 5 years, SIGA Technologies, Inc.

(SIGA) delivered a total return of +1. 4%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: SIGA returned +772. 1% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PLRZ or SIGA or AGEN or NVAX or NRXP?

By beta (market sensitivity over 5 years), Polyrizon Ltd.

(PLRZ) is the lower-risk stock at 0. 65β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 295% more volatile than PLRZ relative to the S&P 500.

05

Which is growing faster — PLRZ or SIGA or AGEN or NVAX or NRXP?

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Polyrizon Ltd. grew EPS 412. 5% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, AGEN leads at 5. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PLRZ or SIGA or AGEN or NVAX or NRXP?

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PLRZ or SIGA or AGEN or NVAX or NRXP more undervalued right now?

On forward earnings alone, SIGA Technologies, Inc.

(SIGA) trades at 2. 8x forward P/E versus 2. 9x for Agenus Inc. — 0. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 95. 5% to $7. 33.

08

Which pays a better dividend — PLRZ or SIGA or AGEN or NVAX or NRXP?

In this comparison, SIGA (12.

7% yield) pays a dividend. PLRZ, AGEN, NVAX, NRXP do not pay a meaningful dividend and should not be held primarily for income.

09

Is PLRZ or SIGA or AGEN or NVAX or NRXP better for a retirement portfolio?

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), 12. 7% yield, +772. 1% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +772. 1%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PLRZ and SIGA and AGEN and NVAX and NRXP?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLRZ is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; AGEN is a small-cap quality compounder stock; NVAX is a small-cap high-growth stock; NRXP is a small-cap quality compounder stock. SIGA pays a dividend while PLRZ, AGEN, NVAX, NRXP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PLRZ

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

SIGA

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 37%
  • Dividend Yield > 5.0%
Run This Screen
Stocks Like

AGEN

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Gross Margin > 21%
Run This Screen
Stocks Like

NVAX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 50%
Run This Screen
Stocks Like

NRXP

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 35%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PLRZ and SIGA and AGEN and NVAX and NRXP on the metrics below

P/E Ratio<
x
(PLRZ: 28.3x · SIGA: 14.3x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.